Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
Authors:
Open Access
- 14 December 2023
- journal article
- research article
- Published by Taylor & Francis in Hematology
- Vol. 29 (1) , 2293512
Abstract
The combination of Venetoclax (VEN) and Azacitidine (AZA) increases survival outcomes and yields excellent responses in patients with acute myeloid leukemia (AML). However, dose reduction (or discontinuation) is commonly encountered due to therapy-related toxicity. Thus, this study aimed to investigate the efficiency and safety of a lower dosage of venetoclax for the treatment of AML. This observational study analyzed the characteristics and outcomes of newly diagnosed AML patients who received 100 mg VEN combined with AZA for 14 days at our institution. A total of 36 patients were enrolled, and the median age at diagnosis was 64 years. After a median follow-up of 15 (range 4-29) months, the median overall survival (OS) and progression-free survival (PFS) for the whole cohort were 17 (4-29) months and 12 (1-28) months, respectively. Meanwhile, the overall response rate (ORR) was 69.4%, and the CRc rate was 66.7% in the whole cohort. Subgroup analysis revealed that NPM1 mutations and FAB-M5 subtype were associated with higher response rates, whereas the adverse ELN risk group was predictive of an inferior response. Moreover, ASXL1, NPM1, and IDH1/2 mutations negatively impacted PFS. Our study optimized the administration of venetoclax plus azacytidine for the treatment of AML patients. Response rates were favorable, with median survival in agreement with the findings of earlier reports, offering valuable insights for optimizing VEN-based regimens. In summary, the VEN combination regimen is effective for the treatment of newly diagnosed AML patients in the real world despite VEN dose reductions .Keywords
All Related Versions
This publication has 23 references indexed in Scilit:
- Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemiaBlood Advances, 2021
- Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practiceAmerican Journal of Hematology, 2021
- Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid MalignanciesHemaSphere, 2021
- Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AMLBlood Advances, 2021
- Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A StudyBlood, 2020
- Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patientsAmerican Journal of Hematology, 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaCancer Discovery, 2020
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AMLBlood, 2020
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016